Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2020)

Monopar Therapeutics' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $18.2 million for Q3 2020.

  • For Q3 2020, Liabilities and Shareholders Equity rose 255.4% year-over-year to $18.2 million; the TTM value through Dec 2020 reached $43.8 million, up 44.03%, while the annual FY2019 figure was $13.4 million, 82.46% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2020 was $18.2 million at Monopar Therapeutics, up from $12.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $18.2 million in Q3 2020 and bottomed at $2.9 million in Q4 2016.
  • The 5-year median for Liabilities and Shareholders Equity is $8.4 million (2018), against an average of $9.2 million.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 35.23% in 2019 before it surged 255.4% in 2020.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.9 million in 2016, then soared by 242.98% to $9.9 million in 2017, then fell by 26.31% to $7.3 million in 2018, then soared by 82.46% to $13.4 million in 2019, then soared by 35.98% to $18.2 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Liabilities and Shareholders Equity are $18.2 million (Q3 2020), $12.8 million (Q2 2020), and $12.8 million (Q1 2020).